Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.315
-$0.005-1.56%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.53M | 12.90M | 16.55M | 17.45M | 17.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.09M | 21.78M | 27.57M | 29.57M | 30.33M |
| Operating Income | -20.09M | -21.78M | -27.57M | -29.57M | -30.33M |
| Income Before Tax | -20.03M | -22.20M | -26.28M | -23.23M | -29.96M |
| Income Tax Expenses | 13.00K | 14.00K | 8.00K | 20.00K | 16.00K |
| Earnings from Continuing Operations | -20.05 | -22.21 | -26.29 | -23.25 | -29.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 142.00K | 66.00K | 15.00K | -- | -- |
| Net Income | -19.90M | -22.14M | -26.28M | -23.25M | -29.98M |
| EBIT | -20.09M | -21.78M | -27.57M | -29.57M | -30.33M |
| EBITDA | -19.70M | -21.37M | -27.17M | -29.18M | -29.93M |
| EPS Basic | -2.49 | -4.34 | -6.38 | -7.15 | -19.99 |
| Normalized Basic EPS | -1.36 | -2.51 | -3.79 | -4.06 | -12.28 |
| EPS Diluted | -2.49 | -4.34 | -6.38 | -7.15 | -19.99 |
| Normalized Diluted EPS | -1.36 | -2.51 | -3.79 | -4.06 | -12.28 |
| Average Basic Shares Outstanding | 55.53M | 32.00M | 20.27M | 13.88M | 9.43M |
| Average Diluted Shares Outstanding | 55.53M | 32.00M | 20.27M | 13.88M | 9.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |